Prelude Therapeutics Incorporated Total Assets | PRLD

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Prelude Therapeutics Incorporated

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
141 M	176 M	278 M	220 M	305 M	224 M	21.9 M	16.4 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
305 M	16.4 M	173 M

Quarterly Total Assets Prelude Therapeutics Incorporated

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
141 M	120 M	176 M	94.8 M	115 M	141 M	278 M	197 M	224 M	247 M	220 M	259 M	281 M	198 M	-	242 M	259 M	281 M	305 M	331 M	350 M	370 M	224 M	224 M	224 M	224 M	21.9 M	21.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
370 M	21.9 M	214 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Repare Therapeutics RPTX	177 M	-	-	$ 112 M	Canada
Sesen Bio SESN	30.5 M	-	7.29 %	$ 127 M	USA
Windtree Therapeutics WINT	27.9 M	-	-	$ 26.8 M	USA
Trean Insurance Group TIG	1.58 B	-	-	$ 316 M	USA
SQZ Biotechnologies Company SQZ	99.9 M	-	57.95 %	$ 12.8 M	USA
MEI Pharma MEIP	42.7 M	-	10.43 %	$ 20.5 M	USA
Palatin Technologies PTN	8.52 M	-	-	$ 13 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Lyra Therapeutics LYRA	36.1 M	-	-	$ 24.9 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Applied Therapeutics APLT	86.7 M	-	-	$ 8.42 M	USA
ESSA Pharma EPIX	128 M	-	-	$ 8.86 M	Canada
Generation Bio Co. GBIO	231 M	-	-	$ 344 M	USA
Clearside Biomedical CLSD	25.1 M	-	-	$ 25.3 M	USA
Merus N.V. MRUS	783 M	-	-	$ 5.78 B	Niderland
RAPT Therapeutics RAPT	240 M	-	-	$ 2.36 B	USA
Annexon ANNX	278 M	$ 4.2	-0.36 %	$ 651 M	USA
AbbVie ABBV	134 B	$ 294.72	0.32 %	$ 521 B	USA
Galmed Pharmaceuticals Ltd. GLMD	18.6 M	$ 4.63	21.05 %	$ 20 M	Israel
Avenue Therapeutics ATXI	2.93 M	-	-52.27 %	$ 4.45 M	USA
Achieve Life Sciences ACHV	41.8 M	$ 6.78	0.89 %	$ 296 M	USA
Axon Enterprise AXON	7 B	$ 316.97	4.77 %	$ 24.7 B	USA
TFF Pharmaceuticals TFFP	12 M	-	-60.05 %	$ 125 K	USA
Bristol-Myers Squibb Company BMY	90 B	$ 62.89	0.18 %	$ 128 B	USA
Adaptimmune Therapeutics plc ADAP	246 M	-	-15.15 %	$ 60.3 M	Britain
Axcella Health AXLA	18.9 M	-	-16.42 %	$ 249 M	USA
Cytokinetics, Incorporated CYTK	1.42 B	$ 58.59	4.29 %	$ 7.04 M	USA
Dynavax Technologies Corporation DVAX	986 M	-	-	$ 2.02 B	USA
Alnylam Pharmaceuticals ALNY	4.97 B	$ 159.75	5.35 %	$ 20.9 B	USA
Amgen AMGN	90.6 B	$ 467.97	0.59 %	$ 252 B	USA
Orgenesis ORGS	1.35 M	-	-33.86 %	$ 61.2 M	USA
Codiak BioSciences CDAK	172 M	-	-55.98 %	$ 2.15 M	USA
Jazz Pharmaceuticals plc JAZZ	11.7 B	$ 248.31	1.17 %	$ 15.1 B	Irlanda
Johnson & Johnson JNJ	199 B	$ 280.31	-0.17 %	$ 675 B	USA
Kala Pharmaceuticals KALA	9.49 M	$ 0.17	0.64 %	$ 1.39 M	USA
BioLineRx Ltd. BLRX	40.9 M	$ 1.49	-1.97 %	$ 3.67 B	Israel
Sage Therapeutics SAGE	547 M	-	-	$ 527 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 1.59	-2.76 %	$ 2.62 M	Israel
Lineage Cell Therapeutics LCTX	113 M	$ 1.13	8.17 %	$ 260 M	USA
Paratek Pharmaceuticals PRTK	173 M	-	-	$ 121 M	USA
TCR2 Therapeutics TCRR	208 M	-	-	$ 58.1 M	USA
C4 Therapeutics CCCC	359 M	$ 2.9	-3.5 %	$ 240 M	USA
Eli Lilly and Company LLY	112 B	$ 1 437.4	0.36 %	$ 1.29 T	USA
ASLAN Pharmaceuticals Limited ASLN	24.6 M	-	-14.27 %	$ 1.7 M	Singapore
Compugen Ltd. CGEN	157 M	$ 2.09	-0.24 %	$ 195 M	Israel
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Crinetics Pharmaceuticals CRNX	1.13 B	$ 84.95	0.13 %	$ 7.99 B	USA